<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01089179</url>
  </required_header>
  <id_info>
    <org_study_id>PK-07- 017</org_study_id>
    <nct_id>NCT01089179</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Metformin Hydrochloride Extended Release 500 mg Tablet Versus Glucophage XR® 500 mg Tablet in Healthy Volunteers Under Fed Conditions</brief_title>
  <official_title>An Open-Label, Randomized, 2-Period, 2-Treatment, Crossover, Single-Dose Bioequivalence Study of Metformin Hydrochloride Extended Release 500 mg Tablet (Test Formulation, Torrent Pharmaceuticals Ltd., India) Versus Glucophage XR® 500 mg Tablet (Reference Formulation, Bristol-Myers Squibb Company, USA) in Healthy Volunteers Under Fed Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Torrent Pharmaceuticals Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Torrent Pharmaceuticals Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective: An Open-Label, Randomized, 2-Period, 2-Treatment, Crossover, Single- Dose&#xD;
      Bioequivalence Study of Metformin Hydrochloride Extended Release 500 mg Tablet (Test&#xD;
      formulation, Torrent Pharmaceuticals Ltd., India) Versus Glucophage XR® 500 mg Tablet&#xD;
      (Reference formulation, Bristol- Myers Squibb company, USA) in Healthy Volunteers under Fed&#xD;
      Conditions.&#xD;
&#xD;
      Study Design: An Open-Label, Randomised, 2-Period, 2-Treatment, Crossover Study under fed&#xD;
      condition.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <number_of_arms>2</number_of_arms>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Torrent's Metformin tablets 500 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Glucophage XR® of Bristol- Myers Squibb Company, USA)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <arm_group_label>Glucophage XR® of Bristol- Myers Squibb Company, USA)</arm_group_label>
    <arm_group_label>Torrent's Metformin tablets 500 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The subjects who qualify for the study should meet the following inclusion criteria.&#xD;
&#xD;
               1. Male subjects in the range of 18 - 45 years of age.&#xD;
&#xD;
               2. Body weight within ± 15% of ideal weight as related to height and body frame&#xD;
                  according to Life Insurance Corporation (LIC) Chart.&#xD;
&#xD;
               3. Subjects with normal findings as determined by baseline history, physical&#xD;
                  examination and vital signs (blood pressure, pulse rate, respiration rate and&#xD;
                  body temperature)&#xD;
&#xD;
               4. Subjects with normal findings as determined by hematological tests, serum&#xD;
                  chemistry, urine analysis, ECG and X-ray.&#xD;
&#xD;
               5. Willingness to follow the protocol requirement as evidenced by written, informed&#xD;
                  consent.&#xD;
&#xD;
               6. Agreeing to, not using any medication (prescription and over the counter),&#xD;
                  including vitamins and minerals for two weeks prior to study &amp; during the course&#xD;
                  of the study.&#xD;
&#xD;
               7. No history or presence of significant alcoholism or drug abuse in the past one&#xD;
                  year.&#xD;
&#xD;
               8. Non-smokers, ex smokers and light smokers will be included. &quot; Light smokers are&#xD;
                  defined as someone smoking 10 cigarettes or less per day, ex smokers as someone&#xD;
                  who completely stopped smoking for at least 3 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The subjects who qualify for the study should not meet the following exclusion&#xD;
             criteria:&#xD;
&#xD;
               1. Requiring medication for any ailment including enzyme-modifying drugs Use of any&#xD;
                  drugs known to induce or inhibit hepatic drug metabolism (e.g.s, inducers:&#xD;
                  barbiturates, carbazepine, phenytoin, glucocorticoids, omeprazole; inhibitors:&#xD;
                  selective serotonin reuptake inhibitors (SSRIs), cimetidine, diltiazem,&#xD;
                  macrolides, imidazoles, neuroleptics, verapamil, fluoroquinolones,&#xD;
                  antihistamines) within 30 days prior to administration of the study medication.&#xD;
&#xD;
               2. Any medical or surgical conditions, which might significantly interfere with the&#xD;
                  functioning of gastrointestinal tract, blood-forming organs etc.&#xD;
&#xD;
               3. History of cardiovascular, renal, hepatic, ophthalmic, pulmonary, neurological,&#xD;
                  metabolic or psychiatric diseases.&#xD;
&#xD;
               4. Participation in a clinical drug study or bioequivalence study 90 days prior to&#xD;
                  present study.&#xD;
&#xD;
               5. History of malignancy or other serious diseases.&#xD;
&#xD;
               6. Refusal to abstain from food for ten (10) hours prior to study drug&#xD;
                  administration on first day of each study period and for four (4) additional&#xD;
                  hours each, post dose.&#xD;
&#xD;
               7. Refusal to abstain from water for one hour pre dose and for two (2) hours, post&#xD;
                  dosing.&#xD;
&#xD;
               8. Any contraindication to blood sampling.&#xD;
&#xD;
               9. Refusal to abstain from smoking or consumption of tobacco products 24 hours&#xD;
                  before dosing until last sample collection of each period. Habituation of tobacco&#xD;
                  necessitating uninterrupted tobacco consumption.&#xD;
&#xD;
              10. Use of xanthine-containing beverages or food for 48 hours prior to each drug&#xD;
                  dose.&#xD;
&#xD;
              11. Blood donation 90 days prior to the commencement of the study.&#xD;
&#xD;
              12. Subjects with positive HIV tests, HbsAg or Hepatitis-C tests.&#xD;
&#xD;
              13. Known history of allergic reactions to Metformin or other related drugs.&#xD;
&#xD;
              14. History of drug abuse in the past one year.&#xD;
&#xD;
              15. Use of prescription medication or over the counter products (including natural&#xD;
                  food supplements,vitamins, garlic as a supplement) within 2 weeks prior to&#xD;
                  administration of study medication, except for topical products without systemic&#xD;
                  absorption.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Torrent Research Centre</name>
      <address>
        <city>Bhat</city>
        <state>Gujarat</state>
        <zip>382 428</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/</url>
    <description>Related Info</description>
  </link>
  <verification_date>March 2010</verification_date>
  <study_first_submitted>March 16, 2010</study_first_submitted>
  <study_first_submitted_qc>March 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2010</study_first_posted>
  <last_update_submitted>May 6, 2010</last_update_submitted>
  <last_update_submitted_qc>May 6, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 7, 2010</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malnutrition</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

